Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Next Previous
Trial Profile

Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Temozolomide
  • Indications Astrocytoma; Glioblastoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 04 Feb 2020 Status changed from active, no longer recruiting to completed.
  • 31 Jul 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.
  • 02 Jun 2015 The phase I results established the MTD and phase II dose of dasatinib to be 150 mg PO daily when given with temozolomide and radiotherapy, according to the abstract presented at ASCO 2015.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top